AI Insight
After two decades of monitoring HPV vaccination programs, evidence is emerging that the vaccine prevents cervical cancer deaths, not just precancerous lesions and cancer incidence. Studies from Sweden, Denmark, and England have shown 84-88% reductions in cervical cancer among vaccinated versus unvaccinated women. A new national-level study from England published in The Lancet provides some of the first data demonstrating that HPV vaccination is associated with reduced cervical cancer mortality.
Why it matters
This represents a critical milestone in demonstrating the full public health impact of HPV vaccination programs, confirming that the vaccine saves lives through mortality reduction. The findings support continued investment in HPV vaccination programs globally and may inform vaccination policies in countries still debating implementation.
Public health has been waiting two decades1,2 for signs that human papillomavirus (HPV) vaccination prevents deaths, not only precancerous lesions and cancer. Studies in countries where HPV vaccination was introduced early have shown substantial decreases in cervical cancer incidence, reporting 84–88% reductions in vaccinated compared with unvaccinated women in studies in Sweden, Denmark, and England.3–5 Now, the impact of HPV vaccination on cervical cancer mortality is emerging,6,7 supported by mortality data from England in a new study in The Lancet by Peter Sasieni and Milena Falcaro,8 which is among the first national-level analyses of cervical cancer mortality following HPV vaccination introduction.
Source: [Comment] HPV vaccination and early declines in cervical cancer deaths